NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE52854 Query DataSets for GSE52854
Status Public on Dec 03, 2013
Title Inhibition of MEK and PI3K alone or in combination alters the transcriptome of the lung during TGFα-induced pulmonary fibrosis
Organism Mus musculus
Experiment type Expression profiling by high throughput sequencing
Summary Pulmonary fibrosis is often triggered by an epithelial injury resulting in the formation of fibrotic lesions in the lung, which progress to impair gas exchange and ultimately cause death. Recent clinical trials using drugs that target either inflammation or a specific molecule have failed, suggesting that multiple pathways and cellular processes need to be attenuated for effective reversal of established and progressive fibrosis. Although activation of MAPK and PI3K pathways have been detected in human fibrotic lung samples, the therapeutic benefits of in vivo modulation of the MAPK and PI3K pathways in combination are unknown. Overexpression of TGFα in the lung epithelium of transgenic mice results in the formation of fibrotic lesions similar to those found in human pulmonary fibrosis, and previous work from our group shows that inhibitors of either the MAPK or PI3K pathway can alter the progression of fibrosis. In this study, we sought to determine whether simultaneous inhibition of the MAPK and PI3K signaling pathways is a more effective therapeutic strategy for established and progressive pulmonary fibrosis. Our results showed that inhibiting both pathways had additive effects compared to inhibiting either pathway alone in reducing fibrotic burden, including reducing lung weight, pleural thickness, and total collagen in the lungs of TGFα mice. This study demonstrates that inhibiting MEK and PI3K in combination abolishes proliferative gene changes associated with fibrosis and myfibroblast accumulation and thus may serve as a therapeutic option in the treatment of human fibrotic lung disease where these pathways play a role.
 
Overall design mRNA profiles of CCSP/TGFalpha mice treated with vehicle, ARRY, PX-866, ARRY/PX-866
 
Contributor(s) Madala SK, Edukulla R, Phatak M, Schmidt S, Davidson C, Acciani TH, Korfhagen TR, Medvedovic M, LeCras TD, Wagner K, Hardie WD
Citation(s) 24475138
Submission date Dec 02, 2013
Last update date Oct 23, 2019
Contact name Mario Medvedovic
Organization name University of Cincinnati
Department Department of Environmental Health
Lab Laboratory for Statistical Genomics and Systems Biology
Street address 3223 Eden Av. ML 56
City Cincinnati
State/province OH
ZIP/Postal code 45267-0056
Country USA
 
Platforms (1)
GPL15103 Illumina HiSeq 1000 (Mus musculus)
Samples (20)
GSM1277067 Normal-1:CCSP/- mice on Doxycycline 8 weeks
GSM1277068 Normal-2:CCSP/- mice on Doxycycline 8 weeks
GSM1277069 Normal-3:CCSP/- mice on Doxycycline 8 weeks
Relations
BioProject PRJNA230367
SRA SRP033407

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE52854_rpkmToUpload.txt.gz 2.9 Mb (ftp)(http) TXT
SRA Run SelectorHelp
Processed data are available on Series record
Raw data are available in SRA

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap